Wednesday, July 8, 2026

biotech · Bladder Cancer · Non Muscle Invasive Bladder Cancer · CGON

CG Oncology

CG Oncology clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Dallas, USA HQ
2010 Founded
187 Employees
Public company Type
CGON · NYSE Ticker
Company details
Status
Public
HQ
Dallas, USA
Founded
2010
Employees
187
Programs
8
Drugs
1
Patents
5
Intelligence · Clinical Programs

CG Oncology projects

2 ClinicalTrials.gov programs sponsored by CG Oncology.

CG Oncology has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CG0070 Adenovirus Vector

    CG Oncology

    Transitional Cell Carcinoma

    phase 3 mab terminated

    1 trial
  2. Cretostimogene Grenadenorepvec

    CG Oncology

    Non Muscle Invasive Bladder Cancer

    phase 3 mab active

    2 trials

Frequently asked questions

How many clinical projects does CG Oncology have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.